Sunday, December 1, 2019

Sun Pharma to defend antitrust claims over delayed entry of 3 generic drugs in US

Sun Pharma to defend antitrust claims over delayed entry of 3 generic drugs in US Sun Pharma said the litigation had already been disclosed in the company#39;s FY19 annual report.

from Moneycontrol Business News https://ift.tt/2ODfudW

No comments:

Post a Comment

Zepto IPO, Swiggy QIP bad news for Eternal investors? Jefferies analysts decode

Jefferies has reiterated its Buy rating on Eternal with a target price of Rs 480, citing strong growth prospects, improving unit economics a...